Volume : 3, Issue : 5, MAY 2017

EVALUATION OF PLASMA CERULOPLASMIN, PLASMA PROTEIN CARBONYL AND ERYTHROCYTE REDUCED GLUTATHIONE LEVEL IN EPITHELIAL CARCINOMA OF OVARY

Dr. Md Hefjur Rahaman, Dr.Sujit Kumar Dey, Dr. Sandeep Jain, Dr.Bilas Kumar Sarkar, Dr. Soumitra Ghosh

Abstract

Background: Ovarian cancer involves all the age groups but is commonest among peri and post menopausal women. It has the gravest prognosis among gynaecological malignancies. Aims &Objectives: To study plasma ceruloplasmin, plasma protein carbonyl and erythrocyte reduced glutathione levels in patients with ovarian malignancies and comparing them with

Aims &Objectives: To study plasma ceruloplasmin, plasma protein carbonyl and erythrocyte reduced glutathione levels in patients with ovarian malignancies and comparing them with age matched controls of similar socioeconomic status, for any statistically significant correlation. Results: The mean and SD of different parameters in the control and test groups were as follows : Protein Carbonyl (1.65± 0.87 & 4.76± 0.17

Results: The mean and SD of different parameters in the control and test groups were as follows : Protein Carbonyl (1.65± 0.87 & 4.76± 0.17 nanomol/mg of total protein), GSH(8.07± 0.28 & 6.81± 0.59 μmol/g of Hb), Ceruloplasmin (28.33± 4.33 & 62.47 ±12.80 mg/dl), CA 125(23.70 ±5.84 & 718.9± 490.58U/ml). By Mann Whitney U test it was concluded that groups are age matched. Protein Carbonyl, ceruloplasmin and CA 125 are significantly increased and GSH was decreased in the test groups. On Spearman's rho correlation, Protein carbonyl was positively correlated with ceruloplasmin and CA125( p<0.005) and negatively with GSH(P<0.005). On post Hoc test, ceruloplasmin,GSH and protein carbonyl were significantly related to the stages but the rise ofCA 125 was not significant on comparing stage 2&3.But it was significantly increased on comparing stage 3&4 with 2&4. Conclusions: It can be concluded that there is increase in oxidative stress with disease progression as evident by increase in Protein Carbonyl and ceruloplasmin and decrease in GSH. Both rise in protein carbonyl and ceruloplasmin can be used as a biomarker for disease progression. There is depletion of GSH with disease progression; further studies are needed to ascertain whether glutathione supplementation can halt the progression of the disease.

Conclusions: It can be concluded that there is increase in oxidative stress with disease progression as evident by increase in Protein Carbonyl and ceruloplasmin and decrease in GSH. Both rise in protein carbonyl and ceruloplasmin can be used as a biomarker for disease progression. There is depletion of GSH with disease progression; further studies are needed to ascertain whether glutathione supplementation can halt the progression of the disease.

Keywords

Ceruloplasmin,Protein Carbonyl, Erythrocyte Reduced Glutathione,Epithelial Carcinoma Ofovary.

Article : Download PDF

Cite This Article

Article No : 14

Number of Downloads : 651

References

1. Chhabra S, Sonak M, Prem V, et al. Gynaecological Malignancies in a Rural Institute in India. J ObstetGynaecol 2002; 22(4):426-9. 2. O’Rourke J, Mahon SM, et al. A Comprehensive Look at the Early Detection of Ovarian Cancer.Clin. J. OncolNurs. 2003; 7 (1):41-7. 3. Edwards BK. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-73. 4. William J Murdoch and James F Martinchick. Oxidative Damage to DNA of Ovarian Surface Epithelial Cells Affected by Ovulation: Carcinogenic Implication and Chemoprevention. Experimental Biol-ogy and Medicine, 2004; 229; 546-552 5. Cancer Risk Factors. Ovulation Stress might Cause Ovarian Cancer. Cancer Weekly 2005 6. Bogdan M, Luciana B, Melissa C. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress Response. Nature Medicine, November 20, 2011, online. 7. Altgelt., Helen LY., Michael McCulloch. Pine street foundation-ovarian cancer,chemotherapy& antioxidant by Johanna 8. Kang DH. Oxidative Stress, DNA Damage, and Breast Cancer. AACN Clin Issues 2002; 13:540-9. 9. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress.ClinChimActa. 2003; 329(1-2):23-38. 10. Valko M, Rhodes CJ, Monocol J. Free radicals, Metals and Antioxidants in Oxidative Stress-induced Cancer. ChemBiol Interact, 2006; 160: 1-40. 11. Kang DH. Oxidative Stress, DNA Damage, and Breast Cancer.AACN Clin Issues.2002; 13:540-9. 12. Ahmed MI, Fayed ST, Hossein H, et al. Lipid Peroxidation and Antioxidant Status in Human Cervical Carcinoma. Dis Markers. 1999; 15(4): 283-91. 13. Ahmed A D, Hye-Yeon C, Jung-Hyun K. Review Role of Oxidative Stress in Stem, Cancer, and Cancer Stem Cells. Cancers. 2010; 2(2):859-884.
Research Paper E-ISSN NO : 2455-295X | VOLUME : 3 | ISSUE : 5 | MAY 2017
I N T E R N A T I O N A L E D U C A T I O N A L S C I E N T I F I C R E S E A R C H J O U R N A L
55
14. Visintin I, Feng Z, Longton G, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008; 14:1065–1072. 15. Verheijen RH, Mensdorff -Pouilly S, van Kamp GJ, et al: CA-125: fundamental and clinical aspects. Semin Cancer Biol 9:117, 1999 16. American College of Obstetricians and Gynecologists: Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 103, April 2009 17. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al: NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer.Version 2. 2011. www.nccn.org. Accessed May 12, 2011 18. Schorge JO, Modesitt SC, Coleman RL, et al: SGO White Paper on ovarian cancer: etiology, screening and surveillance. GynecolOncol 119:7, 2010a 19. American College of Obstetricians and Gynecologists: The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Committee Opinion No. 477, March 2011 20. Nayak SB, Bhat VR, Mayya SS. Serum copper, ceruloplasmin and thiobarbituric acid reactive substance status in patients with ovarian cancer.Indian J PhysiolPharmacol. 2004; 48(4):486-8. 21. Lee CM, Lo HW, Shao RP, et al: Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res. 2004; 64:1788–1793. 22.Nayak S.B., Yashwanth S., Sneha M., Serum Copper,Ceruloplasmin ,ProteinThiols and thiobarbituric acid reactive substance status in Liver Cancer Associated with Elevated levels of Alfa-fetoprotein. Indian J PhysiolPharmacol. 2005; 49 (3): 341–344. 23. Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, Hung MC. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res. 2004; 64(5):1788-93 24. Cancer Res 2009;69 (7):2966–72. 25. Jennifer Z, Mary B T, Yuyan L. Plasma Protein Carbonyls and Breast Cancer Risk in Sisters Discordant for Breast Cancer from the New York Site of the Breast Cancer Family Registry.Cancer Res, 2009 69; 2966. 26. Singh Y P., Sachdeva O P., Aggarwal S K., Chugh K. and Lal H. Blood Glutathione levels in Head and Neck Malignancies. Indian Journal of Clinical Biochemistry, 2008 ; 23 (3) 290-292.